Supplementary Online Content


eTable. Inter-center Treatment of Ocular Adnexal Diffuse Large B-cell Lymphoma (N = 100)

eFigure. Disease-Specific Survival of 57 Patients With Primary Ocular Adnexal Diffuse Large B-cell Lymphoma
<table>
<thead>
<tr>
<th>Treatment</th>
<th>Patiens</th>
<th>Copenhagen</th>
<th>Liverpool</th>
<th>Atlanta</th>
<th>Melbourne</th>
<th>Hyderabad</th>
<th>Houston</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>No. (%)</td>
<td>n = 34</td>
<td>n = 25</td>
<td>n = 6</td>
<td>n = 15</td>
<td>n = 18</td>
<td></td>
</tr>
<tr>
<td>EBRT¹ (+/- surgery)</td>
<td>31 (31)</td>
<td>11</td>
<td>7</td>
<td>2</td>
<td>3</td>
<td>7</td>
<td>1</td>
</tr>
<tr>
<td>Rituximab</td>
<td>+ CHOP or CHOP-like² (+/- EBRT or ASCT³)</td>
<td>21 (21)</td>
<td>1</td>
<td>3</td>
<td>-</td>
<td>-</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>+ Other chemotherapy⁴</td>
<td>9 (9)</td>
<td>4</td>
<td>5</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Rituximab only</td>
<td></td>
<td>1 (1)</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Other chemotherapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other chemotherapy⁴ (+/- EBRT)</td>
<td>19 (19)</td>
<td>6</td>
<td>5</td>
<td>-</td>
<td>3</td>
<td>5</td>
<td>-</td>
</tr>
<tr>
<td>CHOP or CHOP-like² (+/- EBRT or ASCT⁴)</td>
<td>7 (7)</td>
<td>6</td>
<td>1</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Other⁵</td>
<td>12 (12)</td>
<td>5</td>
<td>4</td>
<td>-</td>
<td>-</td>
<td>3</td>
<td>-</td>
</tr>
</tbody>
</table>

Abbreviations:
¹EBRT: external beam radiation therapy.
²CHOP or CHOP-like: cyclophosphamide, hydroxydaunorubicin, vincristine, prednisone.
CHOP-like include CHOEP (CHOP + etoposide), hyper-CVAD (cyclophosphamide, vincristine, adriamycin (hydroxydaunorubicin), prednisone), and EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, hydroxydaunorubicin).
³ASCT: autologous stem cell transplantation.
⁴Other mono- or combination chemotherapy: leukeran, cyclophosphamide, vincristine, etoposide, prednisone, cyt-arabine or cyclophosphamide, methotrexate, 5-flouracil, prednisone.
⁵Other: surgery only, prednisone only, unknown, and no treatment.
*†One patient received ASCT.
A. Increasing T-category of the TNM staging system was associated with disease-specific survival when divided into the T1-T2-T3-T4 main categories ($P = .04$)*.

B. The Ann Arbor Classification was not associated with disease-specific survival ($P = .69$)*.

*The crossed symbols indicate censored patients.